These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 9792827

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Extended analysis of AL-amyloid protein from abdominal wall subcutaneous fat biopsy: kappa IV immunoglobulin light chain.
    Olsen KE, Sletten K, Westermark P.
    Biochem Biophys Res Commun; 1998 Apr 28; 245(3):713-6. PubMed ID: 9588180
    [Abstract] [Full Text] [Related]

  • 3. Identification and location of a cysteinyl posttranslational modification in an amyloidogenic kappa1 light chain protein by electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry.
    Lim A, Wally J, Walsh MT, Skinner M, Costello CE.
    Anal Biochem; 2001 Aug 01; 295(1):45-56. PubMed ID: 11476544
    [Abstract] [Full Text] [Related]

  • 4. Fibril protein fragmentation pattern in systemic AL-amyloidosis.
    Enqvist S, Sletten K, Westermark P.
    J Pathol; 2009 Dec 01; 219(4):473-80. PubMed ID: 19771564
    [Abstract] [Full Text] [Related]

  • 5. ALkappa(I) (UNK) - primary structure of an AL-amyloid protein presenting an organ-limited subcutaneous nodular amyloid syndrome of long duration. Case report and review.
    Wiegel NM, Mentele R, Kellermann J, Meyer L, Riess H, Linke RP.
    Amyloid; 2010 Mar 01; 17(1):10-23. PubMed ID: 20146644
    [Abstract] [Full Text] [Related]

  • 6. Constant region of a kappa III immunoglobulin light chain as a major AL-amyloid protein.
    Engvig JP, Olsen KE, Gislefoss RE, Sletten K, Wahlström O, Westermark P.
    Scand J Immunol; 1998 Jul 01; 48(1):92-8. PubMed ID: 9714416
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.
    Wall JS, Gupta V, Wilkerson M, Schell M, Loris R, Adams P, Solomon A, Stevens F, Dealwis C.
    J Mol Recognit; 2004 Jul 01; 17(4):323-31. PubMed ID: 15227639
    [Abstract] [Full Text] [Related]

  • 9. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
    Davis DP, Gallo G, Vogen SM, Dul JL, Sciarretta KL, Kumar A, Raffen R, Stevens FJ, Argon Y.
    J Mol Biol; 2001 Nov 09; 313(5):1021-34. PubMed ID: 11700059
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunohistochemical study of immunoglobulin light chain amyloidosis with antibodies to the immunoglobulin light chain variable region.
    Hoshii Y, Kiyama M, Cui D, Kawano H, Ishihara T.
    Pathol Int; 2006 Jun 09; 56(6):324-30. PubMed ID: 16704496
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Characterization of an amyloid fibril protein from localized amyloidosis of the skin as lambda immunoglobulin light chains of variable subgroup I (A lambda I).
    Husby G, Sletten K, Blumenkrantz N, Danielsen L.
    Clin Exp Immunol; 1981 Jul 09; 45(1):90-6. PubMed ID: 6796317
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The precursor molecule of a V lambda II-immunoglobulin light chain-derived amyloid fibril protein circulates precleaved.
    Eulitz M, Linke RP.
    Biochem Biophys Res Commun; 1993 Aug 16; 194(3):1427-34. PubMed ID: 8352801
    [Abstract] [Full Text] [Related]

  • 17. Amyloid fibrils derived from V-region together with C-region fragments from a lambda II-immunoglobulin light chain (HAR).
    Eulitz M, Linke R.
    Biol Chem Hoppe Seyler; 1985 Sep 16; 366(9):907-15. PubMed ID: 3935132
    [Abstract] [Full Text] [Related]

  • 18. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
    Bellotti V, Mangione P, Merlini G.
    J Struct Biol; 2000 Jun 16; 130(2-3):280-9. PubMed ID: 10940232
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Application of formalin fixation to the purification of amyloid proteins.
    Layfield R, Bailey K, Dineen R, Mehrotra P, Lowe J, Allibone R, Mayer RJ, Landon M.
    Anal Biochem; 1997 Nov 01; 253(1):142-4. PubMed ID: 9356158
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.